2024-11-22 05:00:00
France has more than 8 million people suffering from obesity. In this context, the arrival on the market of anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you had difficulty losing weight, your options were very limited. These medications are praised by some obesity specialists for their effectiveness. Other health professionals remain cautious and emphasize the lack of perspective on their long-term effects.
In this video, we return to the active ingredient of these new drugs, which imitate a digestive hormone naturally produced by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 1980s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to be eligible for this type of treatment in France, which can only be prescribed by doctors specializing in endocrinology, diabetology or nutrition. Wegogy and Mounjaro are designed to be used as second-line treatment, after failure of nutritional treatment.
To find out more about these new treatments and the excitement they are causing in the financial markets, you will find a complete breakdown below.
Read later
“Understand in three minutes”
The explanatory videos that make up the “Understand in three minutes” series are produced by the Vertical Videos department of the Monde. Broadcast primarily on platforms such as TikTok, Snapchat, Instagram and Facebook, they aim to put major events into context in a short format and make the news accessible to everyone.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
1732280139
#antiobesity #drugs #Wegogy #Mounjaro #work #Understand #minutes
